← All trials
NCT04625361
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2021
- Primary completion
- Sep 30, 2021
- Completion date
- Oct 30, 2021
- First posted
- Nov 12, 2020
- Last posted
- May 10, 2021
- Enrollment
- 102
- Arms / groups
- 10 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.